Results 21 to 30 of about 41,733 (183)

Mutation Profile of Well-Differentiated Thyroid Cancer in Asians [PDF]

Endocrinology and Metabolism, 2015
Recent advances in molecular diagnostics have led to significant insights into the genetic basis of thyroid tumorigenesis. Among the mutations commonly seen in thyroid cancers, the vast majority are associated with the mitogen-activated protein kinase ...
Young Shin Song, Jung Ah Lim, Young Joo Park   +2 more
doaj   +1 more source

The addition of PD-1/PD-L1 axis blockade to BRAF and MEK inhibition for advanced melanoma patients harboring BRAF mutations: a systematic review and meta-analysis

Brazilian Journal of Oncology, 2022
Objectives: Immune-checkpoint inhibitors (ICI) and targeted-therapies (TT) have become standard options for BRAF-V600 metastatic melanomas (MM). Recently, randomized trials (RCT) addressed the efficacy of combined approaches, with conflicting results. We
Mauricio Fernando Silva Almeida Ribeiro, Camila Bragança Xavier, Allan Andresson Lima Pereira, Mariana Scaranti, Luiza Dib Batista Bugiato Faria, Tatiana Strava Correa, Marina Sahade, David Queiroz Borges Muniz, Olavo Feher, Gustavo dos Santos Fernandes, Artur Katz, Rodrigo Ramella Munhoz   +11 more
doaj   +1 more source

Mechanistic Analysis of an Extracellular Signal–Regulated Kinase 2–Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress

Journal of Pharmacology and Experimental Therapeutics, 2020
Constitutively active extracellular signal–regulated kinase (ERK) 1/2 signaling promotes cancer cell proliferation and survival. We previously described a class of compounds containing a 1,1-dioxido-2,5-dihydrothiophen-3-yl 4-benzenesulfonate scaffold ...
Ramon Martinez, Weiliang Huang, R. Samadani, B. Mackowiak, Garrick Centola, Lijia Chen, Ivie L. Conlon, K. Hom, M. Kane, S. Fletcher, P. Shapiro   +10 more
semanticscholar   +1 more source

Risk factors analysis for BRAF gene V600E mutation in patients with infiltrative follicular papillary thyroid carcinoma [PDF]

精准医学杂志
Objective To investigate the risk factors for BRAF gene V600E mutation in patients with infiltrative follicular papillary thyroid carcinoma (IF-PTC). Methods A total of 134 patients with IF-PTC who underwent surgical treatment in our hospital from August
LI Lei, ZHAN Jiezhi, LI Hui, WANG Ruiqing, ZHAO Cheng
doaj   +1 more source

A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors

Exploration of Targeted Anti-tumor Therapy, 2022
Multiple myeloma (MM) is a blood cancer that derives from plasma cells (PCs), which will accumulate in the bone marrow (BM). Over time, several drugs have been developed to treat this disease that is still uncurable.
Vincenzo Raimondi, Nicolas Thomas Iannozzi, Jessica Burroughs-Garcìa, Denise Toscani, Paola Storti, Nicola Giuliani   +5 more
doaj   +1 more source

Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma

Nature Medicine, 2016
The protein kinase B-Raf proto-oncogene, serine/threonine kinase (BRAF) is an oncogenic driver and therapeutic target in melanoma. Inhibitors of BRAF (BRAFi) have shown high response rates and extended survival in patients with melanoma who bear tumors ...
Che-Hung Shen, Sun Hye Kim, S. Trousil, Dennie T. Frederick, A. Piris, P. Yuan, Li Cai, Lei Gu, Man Li, J. H. Lee, D. Mitra, D. Fisher, R. Sullivan, K. Flaherty, B. Zheng   +14 more
semanticscholar   +1 more source

MDM2 induces EMT via the B-Raf signaling pathway through 14-3-3

Oncology Report, 2021
MDM2 proto-oncogene, E3 ubiquitin protein ligase (MDM2) is a well-known oncogene and has been reported to be closely associated with epithelial-to-mesenchymal transition (EMT).
Mengting Ou, Xichao Xu, Ying Chen, Li Li, Lu Zhang, Yi Liao, Weichao Sun, Christine Quach, Jianguo Feng, Liling Tang   +9 more
semanticscholar   +1 more source

BRAF V600E expression in histiocytic sarcoma associated with splenic marginal zone lymphoma: a case report

Journal of Medical Case Reports, 2017
Background Histiocytic sarcoma is a rare histiocytic neoplasm of unknown etiology that constitutes less than 1% of hematologic malignancies. A few cases of histiocytic sarcoma harboring the BRAF V600E mutation have been reported, but this finding has not
John L. Vaughn, C. Eric Freitag, Jessica A. Hemminger, Jeffrey A. Jones   +3 more
doaj   +1 more source

Molecular docking investigation of cytotoxic phenanthrene derivatives

Comptes Rendus. Chimie, 2020
Our previous experimental work indicated that the presence of ester functionality in phenanthrene derivatives D-1 and D-2 leads to potent cytotoxicity against the Caco-2 cell line. The present work is based on th-is experimental result.
Guédouar, Habiba, Zaki, Hanane, Bouachrine, Mohammed, Aloui, Faouzi   +3 more
doaj   +1 more source

Immune check point inhibitors in BRAF mutated metastatic colorectal cancer: A review

International Journal of Gastrointestinal Intervention
Metastatic colorectal cancers with BRAF mutation are a class of tumors that have a poor prognosis compared to wild type patients. Even if this group has found some hope in targeted therapy with multi-targeted blockade of the mitogen-activated protein ...
Alfredo Colombo, Stefano Cordio, Concetta Maria Porretto   +2 more
doaj   +1 more source